Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management

Drugs

Volumn 63, Issue 15, 2003, Pages 1549-1563

  Verstappen, Carla C P ^a   Heimans, Jan J ^a   Hoekman, Klaas ^a   Postma, Tjeerd J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; AMIFOSTINE; AMITRIPTYLINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GANGLIOSIDE; GLUTAMIC ACID; IFOSFAMIDE; METHOTREXATE; NEUROPROTECTIVE AGENT; NITROSOUREA DERIVATIVE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROCARBAZINE; PYRIDOXINE; RECOMBINANT NERVE GROWTH FACTOR; TAXANE DERIVATIVE; VINCA ALKALOID; VINCRISTINE;

ACUTE TOXICITY; APHASIA; ARTICLE; ASEPTIC MENINGITIS; ATAXIA; ATHETOSIS; BLADDER CARCINOMA; BRAIN DISEASE; BRAIN FUNCTION; CANCER CHEMOTHERAPY; CARCINOMA; CEREBELLUM DISEASE; CEREBRAL BLINDNESS; COGNITION; COGNITIVE DEFECT; CONFUSION; CRANIAL NEUROPATHY; DEMENTIA; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG SAFETY; EYE TOXICITY; HEAD CANCER; HEADACHE; HEMIPARESIS; HUMAN; LEUKOENCEPHALOPATHY; LUNG CARCINOMA; MYELORADICULOPATHY; NECK CANCER; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OVARY CARCINOMA; PARKINSONISM; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; SEIZURE; SENSORY DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SPINAL CORD DISEASE; STROKE; STUPOR; TESTIS CARCINOMA; VISUAL IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES;

VINCA;

EID: 0041621727     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363150-00003     Document Type: Article

References (105)

1. Tfayli A, Hentschel P, Madajewicz S, et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol 1999; 42: 73-7
2. Boogerd W, Ten Bokkel Huinink WW, Dalesio O, et al. Cisplatin-induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol 1990; 9: 255-63
3. Lomonaco M, Milone M, Batocchli AP, et al. Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 1992; 239: 199-204
4. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy: frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990; 15: 1117-23
5. Riggs J, Ashraf M, Snyder RD, et al. Prospective nerve conduction studies in cisplatin therapy. Ann Neurol 1988; 23: 92-4
6. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803
7. Dewar J, Lunt H, Abernethy DA, et al. Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry 1986; 49: 96-9
8. van den Bent MJ, van Putten WL, Hilkens PH, et al. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neurotoxicity. Eur J Cancer 2002, 91
9. Gerritsen van der Hoop R, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89-94
10. Neijt J, van der Burg M, Vecht C, et al. A double-blind randomized study with Org 2766, an ACTH(4-9) analog, to prevent cisplatin neuropathy [abstract A827]. Proc ASCO 1994; 13: 261
11. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995; 13: 26-32
12. Kemp G, Rose P, Lurain J. et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12
13. Rick O, Beyer J, Schwella N, et al. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol 2001; 12: 1151-5
14. Gradishar WJ, Stephenson P, Glover DJ, et al. A phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). Cancer 2001; 92: 2517-22
15. Riccardi R, Riccardi A, Di Rocco C, et al. Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors. Cancer Chemother Pharmacol 1992; 30: 21-4
16. O'Brien ME, Tonge K, Blake P, et al. Blindness associated with high-dose carboplatin [letter]. Lancet 1992; 339: 558
17. Markman M, Kennedy A, Webster K, et al. Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol 2001; 127: 55-8
18. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999; 26: 647-62
19. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20: 1767-74
20. Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000; 406: 25-32
21. Eckel F, Schmelz R, Adelsberger H, et al. Prevention of oxaliplatin-induced neuropathy by carbamazepine: a pilot study. Dtsch Med Wochenschr 2002; 127: 78-82
22. Focan C, Olivier R, Le Hung S, et al. Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors. Cancer Chemother Pharmacol 1981; 6: 175-81
23. Romero A, Rabinovich MG, Vallejo CT, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12: 336-41
24. Bain PG, Lantos PL, Djurovic V, et al. Intrathecal vincristine: a fatal chemotherapeutic error with devastating central nervous system effects. J Neurol 1991; 238: 230-4
25. Hurwitz RL, Mahoney DH, Armstrong DL, et al. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 1988; 16: 216-9
26. DeAngelis LM, Gnecco C, Taylor L, et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer 1991; 67: 2241-6
27. Delaney P. Vincristine-induced laryngeal nerve paralysis. Neurology 1982; 32: 1285-8
28. Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy: a clinical study of fifty leukemic patients. Neurology 1969; 19: 367-74
29. Lugassy G, Shapira A. Sensorineural hearing loss associated with vincristine treatment. Blut 1990; 61: 320-1
30. Haim N, Epelbanm R, Ben-Sahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994; 15: 2515-9
31. McLeod JG, Penny R. Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 1969; 32: 297-304
32. Bradley WG, Lassman LP, Pearce GW, et al. The neuromyopathy of vincristine in man: clinical, electrophysiological and pathological studies. J Neurol Sci 1970; 10: 107-31
33. Legha SS. Vincristine neurotoxicity, pathophysiology and management. Meal Toxicol 1986; 1: 421-7
34. Postma TJ, Benard BA, Huijgens PC, et al. Long term effects of vincristine on the peripheral nervous system. J Neurooncol 1993; 15: 23-7
35. Naumann R, Mohm J, Reuner U, et al. Early recognition of hereditary motor and serisory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol 2001; 115: 323-5
36. van Kooten B, van Diemen HA, Groenhout KM, et al. A pilot study on the influence of a corticotropin (4-9) analogue on vinca-alkaloid-induced neuropathy. Arch Neurol 1992; 49: 1027-31
37. Jackson DV, Wells HB, Atkins JN, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988; 84: 1016-22
38. Nieto Y, Cagnoni PJ, Bearman SI, et al. Acute encephalopathy: a new toxicity associated with high dose paclitaxel. Clin Cancer Res 1999; 5: 481-6
39. 2. J Clin Oncol 1994; 12: 1741-2
40. van Gerven JM, Moll JW, van den Bent MJ, et al. Paclitaxel (taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994; 30: 1074-7
41. Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-94
42. Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241-8
43. Freilich RJ, Balmaceda C, Seidman AD, et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115-8
44. Lorenz E, Hagen B, Himmelmann A, et al. A phase II study of biweekly administration of paclitaxel with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 1999; 9: 373-6
45. Jerian SM, Sarosy GA, Link CJ, et al. Incapacitating autonomic neuropathy precipitated by Taxol. Gynecol Oncol 1993; 51: 277-80
46. Sahenk Z, Barohn R, New P, et al. Taxol neuropathy: electrodiagnostic and sural nerve biopsy findings. Arch Neurol 1994; 51: 726-9
47. Kaplan JG, Einzig AI, Schaumburg HH. Taxol causes permanent large fiber peripheral nerve dysfunction: a lesson for preventative strategies. J Neurooncol 1993; 16: 105-7
48. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405-10
49. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39: 368-73
50. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66
51. Martoni A, Zamagni C, Gheka A, et al. Antihistamines in the treatment of taxol-induced paroxystic pain syndrome. J Natl Cancer Inst 1993; 85: 676
52. Apfel SC, Lipton RB, Arezzo JC, et al. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29: 87-90
53. Hamers FP, Pette C, Neijt JP, et al. The ACTH(4-9) analog, Org2766 prevents Taxol-induced neuropathy in rats. Eur J Pharmacol 1993b; 233: 177-8
54. Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 1999; 41: 107-16
55. Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001; 7: 1192-7
56. DiPaola RS, Rodriguez R, Goodin S, et al. Amifostine and dose intense paclitaxel in patients with advanced malignancies. Cancer Ther 1998; 1: 11-7
57. Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 3038-47
58. New PZ, Jackson CE, Rinaldi D, et al. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996; 46: 108-11
59. Hilkens PH, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104-8
60. Vukelja SJ, Baker WJ, Burris III HA, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993; 85: 1432-3
61. Mort MG, Stevenson P, Wood CB. Methotrexate meningitis. Lancet 1972; II: 656
62. Bates S, McKeever P, Masur H, et al. Myelopathy following intrathecal chemotherapy in a patient with extensive Burkitt's lymphoma and altered immune status. Am J Med 1985; 78: 697-702
63. Genvresse I, Dietzmann A, Massenkeil G, et al. Subacute encephalopathy after combination chemotherapy including moderate-dose methotrexate in a patient with gastric cancer. Anticancer Drugs 1999; 10:293-4
64. Kiu MC, Liaw CC, Yang TS, et al. Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma. Anticancer Drugs 1994; 5: 480-2
65. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864-71
66. Lien HH, Blomlie V, Saeter G, et al. Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate. Radiology 1991; 179: 547-50
67. Moore BE, Somers NP, Smith TW. Methotrexate-related non-necrotizing multifocal axonopathy detected by betaamyloid precursor protein immunohistochemistry. Arch Pathol Lab Med 2002; 126: 79-81
68. Koh S, Nelson Jr MD, Kovanlikaya A, et al. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 1999; 21: 576-8
69. Ochs J, Mulhern R, Fairclough D, et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parental methotrexate: a prospective study. J Clin Oncol 1991; 9: 145-51
70. van den Berg H, van der Flier M, van de Wetering MD. Cytarabine-induced aseptic meningitis. Leukemia 2001; 15: 697-9
71. Dunton SF, Nitschke R, Spruce WE, et al. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside: a Pediatric Oncology Group study. Cancer 1986; 57: 1083
72. Kleinschmidt-DeMasters BK, Yeh M. "Locked-in syndrome" after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer 1992; 70: 2504-7
73. Resar LM, Phillips PC, Kastan MB, et al. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993; 71: 117-23
74. Herzig RH, Hines JD, Herzig GP. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987; 5: 927-32
75. Gottlieb D, Bradstock K, Koutts J, et al. The neurotoxicity of high-dose cytosine arabinoside is age related. Cancer 1987; 60: 1439-41
76. Ritch PS, Hansen RM, Heuer DK. Ocular toxicity from high-dose cytosine arabinoside. Cancer 1983; 51: 430-2
77. Shaw PJ, Procopsis PG, Menser MA. Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia. Med Pediatr Oncol 1991; 19: 122-5
78. Hoffman DL, Howard JR Jr, Sarma R, et al. Encephalopathy, myelopathy, optic neuropathy, and anosmia associated with intravenous cytosine arabinoside. Clin Neuropharmacol 1993; 16: 258-62
79. Russell JA, Powles RL. Neuropathy due to cytosine arabinoside. BMJ 1974; 4: 652-3
80. Powell BL, Capizzi RL, Lyerly ES, et al. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin and asparaginase consolidation for acute nonlymphocytic leukemia. J Clin Oncol 1986; 4: 95-7
81. Scherokman B, Filling-Katz MR, Tell D. Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia. Cancer Treat Rep 1985; 69: 1005-6
82. Borgeat A, De Muralt B, Stalder M. Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer 1986; 58: 852-4
83. Courtney MJ, Coffey ET. The mechanism of ara-C-induced apoptosis of differentiating cerebellar granule neurons. Eur J Neurosci 1999; 11: 1073-84
84. Takimoto CH, Lu ZH, Ahang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2: 477-81
85. Bixenman WW, Nicholls JV, Warwick OH. Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol 1977; 83: 789-93
86. Bergevin PR, Patwardhan VC, Weissman J, et al. Neurotoxicity of 5-fluorouracil [letter]. Lancet 1975; I: 410
87. Howell SB, Pfeifle CE, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983; 51: 220-5
88. Israel ZH, Lossos A, Barak V, et al. Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole. Acta Oncol 2000; 39: 117-20
89. Saif MW, Wilson RH, Harold N, et al. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs 2001; 12: 525-31
90. DiMaggio JR, Brown R, Baile WF, et al. Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994; 73: 1509-14
91. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcoma. Results of phase II and pilot studies: dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-84
92. Curtin JP, Koonings PP, Gutierrez M, et al. Ifosfamide-induced neurotoxicity. Gynecol Oncol 1991; 42: 193-6
93. Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986; 4: 1253-61
94. Pelgrims J, de Vos F, van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291-4
95. Kende G, Sirkin SR, Thomas PR, et al. Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer 1979; 44: 69-71
96. Tashima CK. Immediate cerebral symptoms during rapid intravenous administration of cyclophosphamide (NSC-26271). Cancer Chemother Rep 1975; 59: 441-2
97. Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 1982; 100: 1766-72
98. Rosenblum MK, Delattre J-Y, Walker RW, et al. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol 1989; 7: 269-81
99. Wilson WB, Perez GM, Kleinschmidt-DeMasters BK. Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation. Cancer 1987; 59: 901-7
100. Postma TJ, van Groeningen CJ, Witjes RJ, et al. Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 1998; 38: 69-75
101. Spivack SD. Procarbazine. Ann Int Med 1974; 81: 795-800
102. Imrie KR, Couture F, Turner CC, et al. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 77-9
103. Leff RS, Thompson JM, Daly MB, et al. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 1988; 62: 32-5
104. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-8
105. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20: 485-93